Itriglumide

Itriglumide (CR 2945) is an anthranilic acid derivative. Itriglumide is a potent and selective CCKB receptor antagonist, with an IC50 of 2.3 nM. Itriglumide antagonizes the response to gastrin in a dose-dependent manner with an IC50 of 5.9 nM. Itriglumide shows antisecretory and antiulcer activity[1].

Product Specifications

CAS Number

[201605-51-8]

Product Name Alternative

CR 2945

UNSPSC

12352005

Target

Cholecystokinin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/itriglumide.html

Smiles

O=C(C1=C(C(C)=CC(C)=C1)NC(C[C@@H](C2=CC=CC3=CC=CC=C23)CC(O)=O)=O)N4CCC5(CCCC5)CC4

Molecular Formula

C33H38N2O4

Molecular Weight

526.67

References & Citations

[1]Makovec F, et al. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK (B) receptor antagonist. Eur J Pharmacol. 1999 Mar 12;369 (1) :81-90.